Spero reports preliminary cash of ~$109M as of Dec 31, 2022; updates investor presentation

Spero Therapeutics, Inc.

Preliminary cash, cash equivalents and marketable securities of ~$109M as of Dec 31, 2022 (unaudited, subject to change).
Updated investor presentation highlights SPR720 as a potential first-line oral therapy for NTM infections.
Partnerships for tebipenem HBr and SPR206 are noted to support a strong balance sheet.
Audited FY2022 financials are not yet available; preliminary estimate may differ materially.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.